Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s (NYSE:LLY) tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.

Data

Compared with tirzepatide, Wegovy showed a significant 57% greater risk reduction for heart attack, stroke, and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, while on treatment with ...